Mediwound announces additional $9 million in funding from barda to support nexobrid bla resubmission and the expanded access treatment protocol

Yavne, israel, feb. 10, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the biomedical advanced research and development authority (barda), part of the office of the assistant secretary for preparedness and response within the u.s. department of health and human services, has expanded its awarded contract with mediwound by providing supplemental funding of $9 million to support the nexobrid® bla resubmission with the u.s. food and drug administration (fda) and the ongoing expanded access treatment protocol (next).
MDWD Ratings Summary
MDWD Quant Ranking